Kufstein

Researchers are evaluating camizestrant against standard endocrine therapy for patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. These patients must have completed locoregional therapy and at least 2 to 5 years of standard adjuvant endocrine therapy. The study is a Phase III open-label trial focused on improving outcomes for these patients over a long-term period. Participants are randomly assigned to receive either camizestrant orally or continue with the standard endocrine therapy chosen by their investigator, which may include aromatase inhibitors exemestane, letrozole, anastrozole or tamoxifen. Treatment in each group lasts for 60 months. The study allows prior use of CDK46 inhibitors and includes a follow-up period extending up to 10 years from the last patient randomization. During the study, participants will undergo regular assessments to monitor invasive breast cancer-free survival and other outcomes such as invasive disease-free survival, distant relapse-free survival, overall survival, and safety. Researchers will also evaluate symptoms like joint pain, hot flushes, and vaginal dryness using specific scales, along with quality of life measures and pharmacokinetics. Safety monitoring continues up to 28 days after the last dose, and participants remain under observation for up to 10 years total.

Researchers are observing patients with Chronic Lymphocytic Leukemia CLL to better understand this disease which has long been considered incurable except in rare cases involving stem cell transplants. Recent advances like chemoimmunotherapy and new drugs targeting specific disease mechanisms have improved outcomes for some patients, but long-term effects and safety of new treatments remain uncertain. This Austrian registry study aims to systematically collect data on CLL patients across the country to fill this knowledge gap. This study collects information by reviewing existing medical records from multiple centers without altering any treatment plans. It gathers data on patient characteristics, genetic profiles, treatments received, side effects, and disease progression over time. The registry relies solely on routine clinical data already recorded in patient charts, ensuring no extra tests or procedures are required for participation. Participants will be followed longitudinally through their medical records until death or loss to follow-up. Data such as survival, tumor progression, treatment patterns, coexisting conditions, and toxicities are monitored for up to seven years. Personal identifiers are replaced with unique codes to protect confidentiality. The study does not interfere with standard care and requires written consent before data entry from living patients only, with no consent needed for deceased individuals.

Researchers are evaluating a new patient-reported outcome PRO tool designed to detect infections in adults with chronic lymphocytic leukemia CLL or multiple myeloma MM who have secondary immunodeficiency SID. The study aims to improve infection detection and track changes in quality of life over time in this vulnerable group. This observational study is conducted at multiple centers in Germany and Austria and involves patients starting anticancer therapy. Participants will use a mobile app daily to complete electronic PRO questionnaires about infection-related symptoms. Quality of life questionnaires are completed every 1.5 months. Study visits occur every three months to document clinical data such as treatment updates, disease status, and infection history. The app was developed based on a tested software platform and includes features like push reminders to encourage daily symptom reporting. During the year-long participation, researchers will monitor the accuracy of the PRO tool in detecting infections, evaluate adherence to daily reporting, and assess quality of life using validated instruments. Clinical data will be collected and infections documented during quarterly visits. Patient safety and confidentiality are maintained according to ethical standards throughout the study.

Researchers are studying metastatic breast cancer, the most common cancer among women worldwide, with a focus on patients in Austria. This study is the first Austrian-wide registry to systematically collect and document data on metastatic breast cancer cases. The aim is to understand epidemiological trends and treatment patterns, including tumor characteristics and patient outcomes. The study collects both retrospective and prospective data from multiple centers across Austria. It records detailed information on tumor subtypes, initial disease progression, treatment sequences, and patient medical histories. This registry also includes data on male breast cancer patients to assess gender differences in treatment and outcomes. Participants provide anonymized medical information, including tumor characteristics, treatment details, and survival data. Researchers will analyze patterns of metastasis, treatment responses, and survival rates at 1, 2, and 5 years after metastasis diagnosis. The registry aims to offer insights into treatment quality and outcomes over a 10-year period.